Bioengineering strategies for designing targeted cancer therapies

Advances in Cancer Research

Volumn 118, Issue , 2013, Pages 1-59

  Alexander Bryant, Angela A ^a,b   Vanden Berg Foels, Wendy S ^a,b,c,d   Wen, Xuejun ^a,b,c,d,e  

^a AMRL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Virginia Commonwealth University   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; CARBON NANOTUBE; DENDRIMER; EPIDERMAL GROWTH FACTOR; FOLIC ACID; LIPOSOME; MONOCLONAL ANTIBODY; NANOPARTICLE; PEPTIDE; TRANSFERRIN; VASCULOTROPIN;

ARTICLE; BIOENGINEERING; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; EXTRAVASATION; HUMAN; MICELLE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; OPSONIZATION; POLYMERIZATION; PRIORITY JOURNAL;

EID: 84891355094     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407173-5.00002-9     Document Type: Chapter

References (301)

1. ACS (2012). Cancer facts & figures 2012. Atlanta: American Cancer Society.
2. Albanese, A., Tang, P. S., & Chan, W. C. (2012). The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual Review of Biomedical Engineering, 14, 1-16.
3. Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010). Nanoparticle technologies for cancer therapy drug delivery. In M. Schäfer-Korting (Ed.), Handbook of Experimental Pharmacology: Vol. 197. (pp. 55-86). Berlin, Heidelberg: Springer.
4. Ali, H. M., Urbinati, G., Raouane, M., & Massaad-Massade, L. (2012). Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Expert Review of Clinical Pharmacology, 5, 403-412.
5. Allen, T. M. (1998). Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs, 56, 747-756.
6. Anabousi, S., Bakowsky, U., Schneider, M., Huwer, H., Lehr, C. M., & Ehrhardt, C. (2006). In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. European Journal of Pharmaceutical Sciences, 29, 367-374.
7. Arias, J. L. (2011). Drug targeting strategies in cancer treatment: An overview. Mini Reviews in Medicinal Chemistry, 11, 1-17.
8. Asai, T. (2012). Nanoparticle-mediated delivery of anticancer agents to tumor angiogenic vessels. Biological & Pharmaceutical Bulletin, 35, 1855-1861.
9. Backer, M. V., Gaynutdinov, T. I., Patel, V., Bandyopadhyaya, A. K., Thirumamagal, B. T., Tjarks, W., et al. (2005). Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Molecular Cancer Therapeutics, 4, 1423-1429.
10. Bae, Y., Fukushima, S., Harada, A., & Kataoka, K. (2003). Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change. Angewandte Chemie (International Ed. in English), 42, 4640-4643.
11. Banerjee, T., Mitra, S., Kumar Singh, A., Kumar Sharma, R., & Maitra, A. (2002). Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. International Journal of Pharmaceutics, 243, 93-105.
12. Behr, J.-P. (1997). The proton sponge: A trick to enter cells the viruses did not exploit. Chimia (Aarau), 51, 34-36.
13. Bianco, A., Kostarelos, K., & Prato, M. (2005). Applications of carbon nanotubes in drug delivery. Current Opinion in Chemical Biology, 9, 674-679.
14. Bickel, U., Yoshikawa, T., & Pardridge, W. M. (2001). Delivery of peptides and proteins through the blood-brain barrier. Advanced Drug Delivery Reviews, 46, 247-279.
15. Boas, U., & Heegaard, P. M. (2004). Dendrimers in drug research. Chemical Society Reviews, 33, 43-63.
16. Bozec, A., Gros, F. X., Penault-Llorca, F., Formento, P., Cayre, A., Dental, C., et al. (2008). Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. European Journal of Cancer, 44, 1922-1930.
17. Brigger, I., Dubernet, C., & Couvreur, P. (2002). Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 54, 631-651.
18. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., et al. (1994). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79, 1157-1164.
19. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Senger, D. R., et al. (1993). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Research, 53, 4727-4735.
20. Brumlik, M. J., Daniel, B. J., Waehler, R., Curiel, D. T., Giles, F. J., & Curiel, T. J. (2008). Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opinion on Drug Delivery, 5, 87-103.
21. Burgstaller, P., Jenne, A., & Blind, M. (2002). Aptamers and aptazymes: Accelerating small molecule drug discovery. Current Opinion in Drug Discovery & Development, 5, 690-700.
22. Byrne, J. D., Betancourt, T.,&Brannon-Peppas, L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews, 60, 1615-1626.
23. Cabane, E., Zhang, X., Langowska, K., Palivan, C., & Meier, W. (2012). Stimuli-responsive polymers and their applications in nanomedicine. Biointerphases, 7, 1-27.
24. Cao, Y. (2001). Endogenous angiogenesis inhibitors and their therapeutic implications. The International Journal of Biochemistry & Cell Biology, 33, 357-369.
25. Carlsson, J., Kullberg, E. B., Capala, J., Sjoberg, S., Edwards, K., & Gedda, L. (2003). Ligand liposomes and boron neutron capture therapy. Journal of Neuro-Oncology, 62, 47-59.
26. Chang, H. I., & Yeh, M. K. (2012). Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine, 7, 49-60.
27. Chen, H., Khemtong, C., Yang, X., Chang, X., & Gao, J. (2011). Nanonization strategies for poorly water-soluble drugs. Drug Discovery Today, 16, 354-360.
28. Chen, H., Li, L., Cui, S., Mahounga, D., Zhang, J., & Gu, Y. (2011). Folate conjugated CdHgTe quantum dots with high targeting affinity and sensitivity for in vivo early tumor diagnosis. Journal of Fluorescence, 21, 793-801.
29. Chen, H. T., Neerman, M. F., Parrish, A. R., & Simanek, E. E. (2004). Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. Journal of the American Chemical Society, 126, 10044-10048.
30. Chen, Q.-Y., Tao, G.-P., Liu, Y.-Q., & Yang, X. (2012). Synthesis, characterization, cell imaging and anti-tumor activity of multifunctional nanoparticles. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 96, 284-288.
31. Cheng, Y., Meyers, J. D., Agnes, R. S., Doane, T. L., Kenney, M. E., Broome, A. M., et al. (2011). Addressing brain tumors with targeted gold nanoparticles: A new gold standard for hydrophobic drug delivery? Small, 7, 2301-2306.
32. Cho, K., Wang, X., Nie, S., Chen, Z., & Shin, D. M. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research, 14, 1310-1316.
33. Chou, H.-H., Wang, K.-L., Chen, C.-A., Wei, L.-H., Lai, C.-H., Hsieh, C.-Y., et al. (2006). Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up. Gynecologic Oncology, 101, 423-428.
34. Choucair, A., & Eisenberg, A. (2003). Control of amphiphilic block copolymer morphologies using solution conditions. The European Physical Journal. E, Soft Matter, 10, 37-44.
35. Chung, J. E., Yokoyama, M., Aoyagi, T., Sakurai, Y., & Okano, T. (1998). Effect of molecular architecture of hydrophobically modified poly(N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers. Journal of Controlled Release, 53, 119-130.
36. Chung, J. E., Yokoyama, M.,&Okano, T. (2000). Inner core segment design for drug delivery control of thermo-responsive polymeric micelles. Journal of Controlled Release, 65, 93-103.
37. Chung, J. E., Yokoyama, M., Yamato, M., Aoyagi, T., Sakurai, Y., & Okano, T. (1999). Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate). Journal of Controlled Release, 62, 115-127.
38. Corrie, P. G. (2008). Cytotoxic chemotherapy: Clinical aspects. Medicine, 36, 24-28.
39. Crile, G., Jr. (1962). Selective destruction of cancers after exposure to heat. Annals of Surgery, 156, 404-407.
40. Dagar, S., Krishnadas, A., Rubinstein, I., Blend, M. J., & Onyuksel, H. (2003). VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies. Journal of Controlled Release, 91, 123-133.
41. Danhier, F., Feron, O., & Preat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148, 135-146.
42. Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., & Penichet, M. L. (2006). The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clinical Immunology, 121, 144-158.
43. Das, M., Mohanty, C., & Sahoo, S. K. (2009). Ligand-based targeted therapy for cancer tissue. Expert Opinion on Drug Delivery, 6, 285-304.
44. Das, S. K., Sarkar, S., Dash, R., Dent, P., Wang, X.-Y., Sarkar, D., et al. (2012). Chapter one-Cancer terminator viruses and approaches for enhancing therapeutic outcomes. In D. T. Curiel & P. B. Fisher (Eds.), Advances in Cancer Research, Vol. 115, (pp. 1-38). New York: Academic Press.
45. Dash, R., Azab, B., Quinn, B. A., Shen, X., Wang, X. Y., Das, S. K., et al. (2011). Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America, 108, 8785-8790.
46. Davalos, R. V., Mir, I. L., & Rubinsky, B. (2005). Tissue ablation with irreversible electroporation. Annals of Biomedical Engineering, 33, 223-231.
47. Decuzzi, P., & Ferrari, M. (2006). The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials, 27, 5307-5314.
48. Dellian, M., Helmlinger, G., Yuan, F., & Jain, R. K. (1996). Fluorescence ratio imaging of interstitial pH in solid tumours: Effect of glucose on spatial and temporal gradients. British Journal of Cancer, 74, 1206-1215.
49. D'Emanuele, A., & Attwood, D. (2005). Dendrimer-drug interactions. Advanced Drug Delivery Reviews, 57, 2147-2162.
50. De Marre, A., Seymour, L. W., & Schacht, E. (1994). Evaluation of the hydrolytic and enzymatic stability of macromolecular Mitomycin C derivatives. Journal of Controlled Release, 31, 89-97.
51. DeMarre, A., Soyez, H., & Schacht, E. (1994). Synthesis of macromolecular Mitomycin C derivatives. Journal of Controlled Release, 32, 129-137.
52. Deonarain, M. P., Kousparou, C. A., & Epenetos, A. A. (2009). Antibodies targeting cancer stem cells: A new paradigm in immunotherapy? MAbs, 1, 12-25.
53. Devalapally, H., Shenoy, D., Little, S., Langer, R., & Amiji, M. (2007). Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system fortumor-targeted delivery of hydrophobic drugs: Part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemotherapy and Pharmacology, 59, 477-484.
54. Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proceedings of the National Academy of Sciences, 108, 1850-1855.
55. Dijkgraaf, I., Kruijtzer, J. A. W., Frielink, C., Corstens, F. H. M., Oyen, W. J. G., Liskamp, R. M. J., et al. (2007). avb3 Integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. International Journal of Cancer, 120, 605-610.
56. Dong, Y., & Feng, S.-S. (2004). Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials, 25, 2843-2849.
57. Drolet, D. W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., et al. (2000). Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharmaceutical Research, 17, 1503-1510.
58. Duncan, R. (2003). The dawning era of polymer therapeutics. Nature Reviews. Drug Discovery, 2, 347-360.
59. Egusquiaguirre, S., Igartua, M., Hernández, R., & Pedraz, J. (2012). Nanoparticle delivery systems for cancer therapy: Advances in clinical and preclinical research. Clinical & Translational Oncology, 14, 83-93.
60. Ellington, A. D., & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
61. Elnakat, H., & Ratnam, M. (2004). Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Advanced Drug Delivery Reviews, 56, 1067-1084.
62. Etrych, T., Jelinkova, M., Rihova, B., & Ulbrich, K. (2001). New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: Synthesis and preliminary in vitro and in vivo biological properties. Journal of Controlled Release, 73, 89-102.
63. Fajardo, L. F.,&Prionas, S. D. (1994). Endothelial cells and hyperthermia. International Journal of Hyperthermia, 10, 347-353.
64. Fan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994). Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry, 269, 27595-27602.
65. Fang, R. H., & Zhang, L. (2011). Dispersion-based methods for the engineering and manufacture of polymeric nanoparticles for drug delivery applications. Journal of Nanoengineering and Nanomanufacturing, 1, 106-112.
66. Fant, K., Esbjorner, E. K., Jenkins, A., Grossel, M. C., Lincoln, P., & Norden, B. (2010). Effects of PEGylation and acetylation of PAMAM dendrimers on DNA binding, cytotoxicity and in vitro transfection efficiency. Molecular Pharmaceutics, 7, 1734-1746.
67. Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004). Nanoparticle-aptamer bioconjugates. Cancer Research, 64, 7668-7672.
68. Farokhzad, O. C., Karp, J. M., & Langer, R. (2006). Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opinion on Drug Delivery, 3, 311-324.
69. Farokhzad, O. C., Khademhosseini, A., Jon, S., Hermmann, A., Cheng, J., Chin, C., et al. (2005). Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Analytical Chemistry, 77, 5453-5459.
70. Faulk, W. P., Taylor, C. G., Yeh, C. J., & McIntyre, J. A. (1990). Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Molecular Biotherapy, 2, 57-60.
71. Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007). Soluble singlewalled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. Journal of the American Chemical Society, 129, 8438-8439.
72. Felgner, J. H., Kumar, R., Sridhar, C. N., Wheeler, C. J., Tsai, Y. J., Border, R., et al. (1994). Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. Journal of Biological Chemistry, 269, 2550-2561.
73. Ferrara, N. (2005). VEGF as a therapeutic target in cancer. Oncology, 69(Suppl. 3), 11-16.
74. Frechet, J. M. (2002). Dendrimers and supramolecular chemistry. Proceedings of the National Academy of Sciences of the United States of America, 99, 4782-4787.
75. Fresta, M., Puglisi, G., Giammona, G., Cavallaro, G., Micali, N., & Furneri, P. M. (1995). Pefloxacine mesilate-and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: Characterization of the colloidal drug carrier formulation. Journal of Pharmaceutical Sciences, 84, 895-902.
76. Gaber, M. H., Wu, N. Z., Hong, K., Huang, S. K., Dewhirst, M. W., & Papahadjopoulos, D. (1996). Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks. International Journal of Radiation Oncology, Biology, Physics, 36, 1177-1187.
77. Gao, W., Chan, J. M., & Farokhzad, O. C. (2010). pH-Responsive nanoparticles for drug delivery. Molecular Pharmaceutics, 7, 1913-1920.
78. Gao, H., Qian, J., Cao, S., Yang, Z., Pang, Z., Pan, S., et al. (2012). Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials, 33, 5115-5123.
79. Gao, W., Xiao, Z., Radovic-Moreno, A., Shi, J., Langer, R., & Farokhzad, O. C. (2010). Progress in siRNA delivery using multifunctional nanoparticles. Methods in Molecular Biology, 629, 53-67.
80. Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E., & Mason, D. Y. (1983). Transferrin receptors in human tissues: Their distribution and possible clinical relevance. Journal of Clinical Pathology, 36, 539-545.
81. Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., et al. (2007). Shape effects of filaments versus spherical particles in flow and drug delivery. Nature Nanotechnology, 2, 249-255.
82. Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2010). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS Journal, 278, 16-27.
83. Gillies, E. R., & Frechet, J. M. (2005). pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjugate Chemistry, 16, 361-368.
84. Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012). Polymeric micelles drug delivery system in oncology. Journal of Controlled Release, 159, 312-323.
85. Gong, W., Wang, Z., Liu, N., Lin, W., Wang, X., Xu, D., et al. (2011). Improving Efficiency of Adriamycin Crossing Blood Brain Barrier by Combination of Thermosensitive Liposomes and Hyperthermia. Biological & Pharmaceutical Bulletin, 34, 1058-1064.
86. Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annual Review of Medicine, 53, 615-627.
87. Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews. Cancer, 2, 48-58.
88. Graff, A., Tropel, D., Raman, S. K., Machaidze, G., Aebi, U., & Burkhard, P. (2005). Peptidic nanoparticles: For cancer diagnosis and therapy. NanoBiotechnology, 1, 293-294.
89. Graham, M. M., & Menda, Y. (2011). Radiopeptide imaging and therapy in the United States. Journal of Nuclear Medicine, 52(Suppl. 2), 56S-63S.
90. Greco, A., Di Benedetto, A., Howard, C. M., Kelly, S., Nande, R., Dementieva, Y., et al. (2010). Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Molecular Therapy, 18, 295-306.
91. Gref, R., Luck, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., et al. (2000). 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the corecomposition on phagocytic uptake and plasma protein adsorption. Colloids and Surfaces. B, Biointerfaces, 18, 301-313.
92. Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994). Biodegradable long-circulating polymeric nanospheres. Science, 263, 1600-1603.
93. Griffiths, G., Nystrom, B., Sable, S. B., & Khuller, G. K. (2010). Nanobead-based interventions for the treatment and prevention of tuberculosis. Nature Reviews. Microbiology, 8, 827-834.
94. Gu, F. X., Karnik, R., Wang, A. Z., Alexis, F., Levy-Nissenbaum, E., Hong, S., et al. (2007). Targeted nanoparticles for cancer therapy. Nano Today, 2, 14-21.
95. Haley, B., & Frenkel, E. (2008). Nanoparticles for drug delivery in cancer treatment. Urologic Oncology, 26, 57-64.
96. Hans, M. L., & Lowman, A. M. (2002). Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State and Materials Science, 6, 319-327.
97. Head, J. F., Wang, F., & Elliott, R. L. (1997). Antineoplastic drugs that interfere with iron metabolism in cancer cells. Advances in Enzyme Regulation, 37, 147-169.
98. Hicke, B. J., & Stephens, A. W. (2000). Escort aptamers: A delivery service for diagnosis and therapy. The Journal of Clinical Investigation, 106, 923-928.
99. Hilgenbrink, A. R., & Low, P. S. (2005). Folate receptor-mediated drug targeting: From therapeutics to diagnostics. Journal of Pharmaceutical Sciences, 94, 2135-2146.
100. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., et al. (1998). Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 95, 4607-4612.
101. Hölig, P., Bach, M., Völkel, T., Nahde, T., Hoffmann, S., Müller, R., et al. (2004). Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Engineering, Design & Selection, 17, 433-441.
102. Honer, M., Mu, L., Stellfeld, T., Graham, K., Martic, M., Fischer, C. R., et al. (2011). 18Flabeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. Journal of Nuclear Medicine, 52, 270-278.
103. Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., et al. (2002). Tumor regression by targeted gene delivery to the neovasculature. Science, 296, 2404-2407.
104. Hosokawa, T., Sami, M., Kato, Y., & Hayakawa, E. (2003). Alteration in the temperaturedependent content release property of thermosensitive liposomes in plasma. Chemical & Pharmaceutical Bulletin (Tokyo), 51, 1227-1232.
105. Hoste, K., De Winne, K., & Schacht, E. (2004). Polymeric prodrugs. International Journal of Pharmaceutics, 277, 119-131.
106. Hou, J., Zhang, Q., Li, X., Tang, Y., Cao, M. R., Bai, F., et al. (2011). Synthesis of novel folate conjugated fluorescent nanoparticles for tumor imaging. Journal of Biomedical Materials Research. Part A, 99, 684-689.
107. Howlader, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., et al. (2011). SEER cancer statistics review, 1975-2008. Bethesda,MD: National Cancer Institute.
108. Hu, C. M., & Zhang, L. (2009). Therapeutic nanoparticles to combat cancer drug resistance. Current Drug Metabolism, 10, 836-841.
109. Huang, Y. F., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., et al. (2009). Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem, 10, 862-868.
110. Hughes, G. A. (2005). Nanostructure-mediated drug delivery. Nanomedicine, 1, 22-30.
111. Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Research, 65, 8984-8992.
112. Husseini, G. A., & Pitt, W. G. (2008). Micelles and nanoparticles for ultrasonic drug and gene delivery. Advanced Drug Delivery Reviews, 60, 1137-1152.
113. Iinuma, H., Maruyama, K., Okinaga, K., Sasaki, K., Sekine, T., Ishida, O., et al. (2002). Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. International Journal of Cancer, 99, 130-137.
114. Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today, 11, 812-818.
115. Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., et al. (1998). Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proceedings of the National Academy of Sciences of the United States of America, 95, 10820-10825.
116. Jeong, B., Bae, Y. H., & Kim, S. W. (2000). Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers. Journal of Controlled Release, 63, 155-163.
117. Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Medicine, 12, 1167-1174.
118. Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011). Nanoparticle PEGylation for imaging and therapy. Nanomedicine (London, England), 6, 715-728.
119. Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002). Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. Journal of Controlled Release, 82, 189-212.
120. Kaczorowska, M. A., & Cooper, H. J. (2008). Electron capture dissociation, electron detachment dissociation, and collision-induced dissociation of polyamidoamine (PAMAM) dendrimer ions with amino, amidoethanol, and sodium carboxylate surface groups. Journal of the American Society for Mass Spectrometry, 19, 1312-1319.
121. Kakar, S. S., Jin, H., Hong, B., Eaton, J. W., Kang, K. A., Kang, K. A., et al. (2008). LHRH receptor targeted therapy for breast cancer oxygen transport to tissue XXIX (Vol. 614). New York: Springer, 285-296.
122. Kam, N. W.,&Dai, H. (2005). Carbon nanotubes as intracellular protein transporters:Generality and biological functionality. Journal of the American Chemical Society, 127, 6021-6026.
123. Kamada, H., Tsutsumi, Y., Yoshioka, Y., Yamamoto, Y., Kodaira, H., Tsunoda, S., et al. (2004). Design of a pH-sensitive polymeric carrier for drug release and its application in cancer therapy. Clinical Cancer Research, 10, 2545-2550.
124. Kaminskas, L. M., Boyd, B. J., & Porter, C. J. (2011). Dendrimer pharmacokinetics: The effect of size, structure and surface characteristics on ADME properties. Nanomedicine (London, England), 6, 1063-1084.
125. Kaneko,Y.,Nakamura, S., Sakai, K., Kikuchi, A.,Aoyagi,T.,Sakurai,Y., et al. (1999). Synthesis and swelling-deswelling kinetics of poly(N-isopropylacrylamide) hydrogels grafted with LCST modulated polymers. Journal of Biomaterials Science. Polymer Edition, 10, 1079-1091.
126. Kaptain, S., Tan, L. K., & Chen, B. (2001). Her-2/neu and breast cancer. Diagnostic Molecular Pathology, 10, 139-152.
127. Kedar, U., Phutane, P., Shidhaye, S., & Kadam, V. (2010). Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine, 6, 714-729.
128. Khajavinia, A., Varshosaz, J., & Dehkordi, A. J. (2012). Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology, 23, 405101.
129. Kim, S., Kim, J.-H., Jeon, O., Kwon, I. C., & Park, K. (2009). Engineered polymers for advanced drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 71, 420-430.
130. Kim, S., Shi, Y., Kim, J. Y., Park, K., & Cheng, J.-X. (2010). Overcoming the barriers in micellar drug delivery: Loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opinion on Drug Delivery, 7, 49-62.
131. Kitchens, D. L., Snyder, E. Y., & Gottlieb, D. I. (1994). FGF and EGF are mitogens for immortalized neural progenitors. Journal of Neurobiology, 25, 797-807.
132. Klein, S., & Levitzki, A. (2007). Targeted cancer therapy: Promise and reality. In George F. Vande Woude & George Klein (Eds.), Advances in Cancer Research, Vol. 97, (pp. 295-319). New York: Academic Press.
133. Kobayashi, T. (2011). Cancer hyperthermia using magnetic nanoparticles. Biotechnology Journal, 6, 1342-1347.
134. Kobayashi, T., Ishida, T., Okada, Y., Ise, S., Harashima, H., & Kiwada, H. (2007). Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. International Journal of Pharmaceutics, 329, 94-102.
135. Kolhatkar, R. B., Kitchens, K. M., Swaan, P. W., & Ghandehari, H. (2007). Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjugate Chemistry, 18, 2054-2060.
136. Kong, G., Braun, R. D., & Dewhirst, M. W. (2001). Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Research, 61, 3027-3032.
137. Koo, Y.-E. L., Reddy, G. R., Bhojani, M., Schneider, R., Philbert, M. A., Rehemtulla, A., et al. (2006). Brain cancer diagnosis and therapy with nanoplatforms. Advanced Drug Delivery Reviews, 58, 1556-1577.
138. Kos, J., Obermajer, N., Doljak, B., Kocbek, P., & Kristl, J. (2009). Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. International Journal of Pharmaceutics, 381, 106-112.
139. Kremer, C., Breier, G., Risau, W., & Plate, K. H. (1997). Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Research, 57, 3852-3859.
140. Kreuter, J. (2001). Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews, 47, 65-81.
141. Kukowska-Latallo, J. F., Candido, K. A., Cao, Z., Nigavekar, S. S., Majoros, I. J., Thomas, T. P., et al. (2005). Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Research, 65, 5317-5324.
142. Kullberg, E. B., Nestor, M., & Gedda, L. (2003). Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: Uptake and processing. Pharmaceutical Research, 20, 229-236.
143. Kumari, A., Yadav, S. K., & Yadav, S. C. (2009). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces. B, Biointerfaces, 75, 1-18.
144. Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (1994). Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates. Journal of Controlled Release, 29, 17-23.
145. Labieniec, M., Ulicna, O., Vancova, O., Kucharska, J., Gabryelak, T., & Watala, C. (2009). Effect of poly(amido)amine (PAMAM) G4 dendrimer on heart and liver mitochondria in an animal model of diabetes. Cell Biology International, 34, 89-97.
146. Lacroix, M. (2008). Persistent use of "false" cell lines. International Journal of Cancer, 122, 1-4.
147. Laske, D. W., Youle, R. J., & Oldfield, E. H. (1997). Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Medicine, 3, 1362-1368.
148. Laskin, J. J., & Sandler, A. B. (2004). Epidermal growth factor receptor: A promising target in solid tumours. Cancer Treatment Reviews, 30, 1-17.
149. Lee, R. J., & Low, P. S. (1994). Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. Journal of Biological Chemistry, 269, 3198-3204.
150. Lee, C. C., MacKay, J. A., Frechet, J. M., & Szoka, F. C. (2005). Designing dendrimers for biological applications. Nature Biotechnology, 23, 1517-1526.
151. Lee, R. J., Wang, S., & Low, P. S. (1996). Measurement of endosome pH following folate receptor-mediated endocytosis. Biochimica et Biophysica Acta, 1312, 237-242.
152. Lee, P., Zhang, R., Li, V., Liu, X., Sun, R. W., Che, C. M., et al. (2012). Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. International Journal of Nanomedicine, 7, 731-737.
153. Leemans, C. R., Braakhuis, B. J. M., & Brakenhoff, R. H. (2011). The molecular biology of head and neck cancer. Nature Reviews. Cancer, 11, 9-22.
154. Leslie, E. M., Deeley, R. G., & Cole, S. P. (2005). Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology, 204, 216-237.
155. Li, X., Zhou, H., Yang, L., Du, G., Pai-Panandiker, A. S., Huang, X., et al. (2011). Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles. Biomaterials, 32, 2540-2545.
156. Liang, F., & Chen, B. (2010). A review on biomedical applications of single-walled carbon nanotubes. Current Medicinal Chemistry, 17, 10-24.
157. Liechty, W. B., & Peppas, N. A. (2012). Expert opinion: Responsive polymer nanoparticles in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 80, 241-246.
158. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., et al. (2001). Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biology, 3, 802-808.
159. Liu, Z., Chen, K., Davis, C., Sherlock, S., Cao, Q., Chen, X., et al. (2008). Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Research, 68, 6652-6660.
160. Liu, D.-Z., Hsieh, J.-H., Fan, X.-C., Yang, J.-D., & Chung, T.-W. (2007). Synthesis, characterization and drug delivery behaviors of new PCP polymeric micelles. Carbohydrate Polymers, 68, 544-554.
161. Liu, Y., Miyoshi, H., &Nakamura, M. (2007). Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. International Journal of Cancer, 120, 2527-2537.
162. Liu, D., Mori, A., & Huang, L. (1992). Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochimica et Biophysica Acta, 1104, 95-101.
163. Liu, Z., Sun, X., Nakayama-Ratchford, N., & Dai, H. (2007). Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano, 1, 50-56.
164. Loh, X. J., Yee, B. J. H., & Chia, F. S. (2012). Sustained delivery of paclitaxel using thermogelling poly(PEG/PPG/PCL urethane)s for enhanced toxicity against cancer cells. Journal of Biomedical Materials Research. Part A, 100, 2686-2694.
165. Lorusso, V., Manzione, L., & Silvestris, N. (2007). Role of liposomal anthracyclines in breast cancer. Annals of Oncology, 18, vi70-vi73.
166. Lovett, K. M., Liang, B. A., & Mackey, T. K. (2012). Risks of online direct-to-consumer tumor markers for cancer screening. Journal of Clinical Oncology, 30, 1411-1414.
167. Low, P. S., & Antony, A. C. (2004). Folate receptor-targeted drugs for cancer and inflammatory diseases. Advanced Drug Delivery Reviews, 56, 1055-1058.
168. Low, P. S., & Kularatne, S. A. (2009). Folate-targeted therapeutic and imaging agents for cancer. Current Opinion in Chemical Biology, 13, 256-262.
169. Lu, J., Jackson, J. K., Gleave, M. E., & Burt, H. M. (2008). The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemotherapy and Pharmacology, 61, 997-1005.
170. Lu, Y., & Low, P. S. (2002). Folate-mediated delivery of macromolecular anticancer therapeutic agents. Advanced Drug Delivery Reviews, 54, 675-693.
171. Lurje, G., & Lenz, H. J. (2009). EGFR signaling and drug discovery. Oncology, 77, 400-410.
172. Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation, 41, 189-207.
173. Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009). Polymeric drugs for efficient tumortargeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and Biopharmaceutics, 71, 409-419.
174. Maeda, H., Sawa, T., & Konno, T. (2001). Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. Journal of Controlled Release, 74, 47-61.
175. Malam, Y., Loizidou, M., &Seifalian, A. M. (2009). Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends in Pharmacological Sciences, 30, 592-599.
176. Malik, A. K., & Gerber, H.-P. (2003). Targeting VEGF ligands and receptors in cancer. Targets, 2, 48-57.
177. Malik, N., Wiwattanapatapee, R., Klopsch, R., Lorenz, K., Frey, H., Weener, J. W., et al. (2000). Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. Journal of Controlled Release, 65, 133-148.
178. Masson, O., Prebois, C., Derocq, D., Meulle, A., Dray, C., Daviaud, D., et al. (2011). Cathepsin-D, a key protease in breast cancer, is up-regulated in obese mouse and human adipose tissue, and controls adipogenesis. PLoS One, 6, e16452.
179. Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46, 6387-6392.
180. Medina, S. H., & El-Sayed, M. E. H. (2009). Dendrimers as carriers for delivery of chemotherapeutic agents. Chemical Reviews, 109, 3141-3157.
181. Meng, S., Su, B., Li, W., Ding, Y., Tang, L., Zhou, W., et al. (2010). Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nanotechnology, 21, 415103.
182. Merdan, T., Kopecek, J., & Kissel, T. (2002). Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Advanced Drug Delivery Reviews, 54, 715-758.
183. Milhem, O. M., Myles, C., McKeown, N. B., Attwood, D., & D'Emanuele, A. (2000). Polyamidoamine Starburst dendrimers as solubility enhancers. International Journal of Pharmaceutics, 197, 239-241.
184. Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005). Nanomedicine: Current status and future prospects. The FASEB Journal, 19, 311-330.
185. Mohanty, C., Das, M., Kanwar, J. R., & Sahoo, S. K. (2011). Receptor mediated tumor targeting: An emerging approach for cancer therapy. Current Drug Delivery, 8, 45-58.
186. Momekova, D., Rangelov, S., Yanev, S., Nikolova, E., Konstantinov, S., Romberg, B., et al. (2007). Long-circulating, pH-sensitive liposomes sterically stabilized by copolymers bearing short blocks of lipid-mimetic units. European Journal of Pharmaceutical Sciences, 32, 308-317.
187. Montet, X., Funovics, M., Montet-Abou, K., Weissleder, R., & Josephson, L. (2006). Multivalent effects of RGD peptides obtained by nanoparticle display. Journal of Medicinal Chemistry, 49, 6087-6093.
188. Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., et al. (2008). Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proceedings of the National Academy of Sciences of the United States of America, 105, 9343-9348.
189. Nakamura, K., Abu Lila, A. S., Matsunaga, M., Doi, Y., Ishida, T., & Kiwada, H. (2011). A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Molecular Therapy, 19, 2040-2047.
190. Nakayama, M., Okano, T., Miyazaki, T., Kohori, F., Sakai, K., & Yokoyama, M. (2006). Molecular design of biodegradable polymeric micelles for temperature-responsive drug release. Journal of Controlled Release, 115, 46-56.
191. Napier, M. P., Sharma, S. K., Springer, C. J., Bagshawe, K. D., Green, A. J., Martin, J., et al. (2000). Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. Clinical Cancer Research, 6, 765-772.
192. Nigavekar, S. S., Sung, L. Y., Llanes, M., El-Jawahri, A., Lawrence, T. S., Becker, C. W., et al. (2004). 3H dendrimer nanoparticle organ/tumor distribution. Pharmaceutical Research, 21, 476-483.
193. Nimjee, S. M., Rusconi, C. P., Harrington, R. A., & Sullenger, B. A. (2005). The potential of aptamers as anticoagulants. Trends in Cardiovascular Medicine, 15, 41-45.
194. Norman, J., Badie-Dezfooly, B.,Nord, E. P.,Kurtz, I., Schlosser, J.,Chaudhari,A., et al. (1987). EGF-induced mitogenesis in proximal tubular cells:Potentiation by angiotensin II. American Journal of Physiology. Renal Physiology, 253, F299-F309.
195. Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J., & Hennink, W. (2010). Polymeric micelles in anticancer therapy: Targeting, imaging and triggered release. Pharmaceutical Research, 27, 2569-2589.
196. Ohlsson, B., Rehfeld, J. F., & Axelson, J. (1999). CCK stimulates growth of both the pancreas and the liver. International Journal of Surgical Investigation, 1, 47-54.
197. Onyuksel, H., Mohanty, P. S.,&Rubinstein, I. (2009). VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: A novel targeted nanomedicine for breast cancer. International Journal of Pharmaceutics, 365, 157-161.
198. Owens, D. E., III., & Peppas, N. A. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 307, 93-102.
199. Pantarotto, D., Briand, J. P., Prato, M., & Bianco, A. (2004). Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chemical Communications (Cambridge, England), 1, 16-17.
200. Panyam, J., & Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews, 55, 329-347.
201. Pardridge, W. M. (2002). Drug and gene delivery to the brain: The vascular route. Neuron, 36, 555-558.
202. Parhi, P., Mohanty, C., & Sahoo, S. K. (2012). Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy. Drug Discovery Today, 17, 1044-1052.
203. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., et al. (2002). Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clinical Cancer Research, 8, 1172-1181.
204. Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., et al. (2001). Tumor targeting using anti-her2 immunoliposomes. Journal of Controlled Release, 74, 95-113.
205. Park, E. K., Lee, S. B., & Lee, Y. M. (2005). Preparation and characterization of methoxy poly(ethylene glycol)/poly(Îm-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials, 26, 1053-1061.
206. Parveen, S., Misra, R., & Sahoo, S. K. (2012). Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine, 8, 147-166.
207. Pastorino, F., Brignole, C., Di Paolo, D., Nico, B., Pezzolo, A., Marimpietri, D., et al. (2006). Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Research, 66, 10073-10082.
208. Patri, A. K., Majoros, I. J., & Baker, J. R. (2002). Dendritic polymer macromolecular carriers for drug delivery. Current Opinion in Chemical Biology, 6, 466-471.
209. Peng, C.-L., Tsai, H.-M., Yang, S.-J., Luo, T.-Y., Lin, C.-F., Lin, W.-J., et al. (2011). Development of thermosensitive poly(N-isopropylacrylamide-co-((2-dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release. Nanotechnology, 22, 265608.
210. Peracchia, M. T., Fattala, E., Desmaëleb, D., Besnarda, M., Noëlc, J. P., Gomisc, J. M., et al. (1999). Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. Journal of Controlled Release, 60, 121-128.
211. Perrault, S. D.,Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009). Mediating tumor targeting efficiency of nanoparticles through design. Nano Letters, 9, 1909-1915.
212. Pestourie, C., Tavitian, B., & Duconge, F. (2005). Aptamers against extracellular targets for in vivo applications. Biochimie, 87, 921-930.
213. Podgorski, I., & Sloane, B. F. (2003). Cathepsin B and its role(s) in cancer progression. Biochemical Society Symposium, 70, 263-276.
214. Prakash, S., Malhotra, M., Shao, W., Tomaro-Duchesneau, C., & Abbasi, S. (2011). Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Advanced Drug Delivery Reviews, 63, 1340-1351.
215. Pulkkinen, M., Pikkarainen, J., Wirth, T., Tarvainen, T., Haapa-aho, V., Korhonen, H., et al. (2008). Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. European Journal of Pharmaceutics and Biopharmaceutics, 70, 66-74.
216. Purushotham, S., Chang, P., Rumpel, H., Kee, I., Ng, R., Chow, P., et al. (2009). Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy. Nanotechnology, 20, 305101.
217. Radinsky, R., Risin, S., Fan, D., Dong, Z., Bielenberg, D., Bucana, C. D., et al. (1995). Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clinical Cancer Research, 1, 19-31.
218. Rainov, N. G., & Soling, A. (2005). Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine. Current Opinion in Molecular Therapeutics, 7, 483-492.
219. Reubi, J. C. (2003). Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Reviews, 24, 389-427.
220. Roberts, J. C., Bhalgat, M. K., & Zera, R. T. (1996). Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. Journal of Biomedical Materials Research, 30, 53-65.
221. Roda, E., Coccini, T., Acerbi, D., Barni, S., Vaccarone, R., & Manzo, L. (2011). Comparative pulmonary toxicity assessment of pristine and functionalized multi-walled carbon nanotubes intratracheally instilled in rats: Morphohistochemical evaluations. Histology and Histopathology, 26, 357-367.
222. Rubin, P., & Casarett, G. (1966). Microcirculation of tumors. I. Anatomy, function, and necrosis. Clinical Radiology, 17, 220-229.
223. Sahoo, S. K., & Labhasetwar, V. (2003). Nanotech approaches to drug delivery and imaging. Drug Discovery Today, 8, 1112-1120.
224. Sahoo, S. K., & Labhasetwar, V. (2005). Enhanced antiproliferative activity of transferrinconjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Molecular Pharmaceutics, 2, 373-383.
225. Sahoo, S. K., Ma, W., & Labhasetwar, V. (2004). Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. International Journal of Cancer, 112, 335-340.
226. Saito, Y., Yasunaga, M., Kuroda, J.-I., Koga, Y., & Matsumura, Y. (2007). Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. European Journal of Cancer, 46, 650-658.
227. Sakai, K., Mori, S., Kawamoto, T., Taniguchi, S., Kobori, O., Morioka, Y., et al. (1986). Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. Journal of the National Cancer Institute, 77, 1047-1052.
228. Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology, 19, 183-232.
229. Sampathkumar, S.-G., & Yarema, K. J. (2007). Nanomaterials for cancer diagnosis. In Nanotechnologies for the life sciences: Vol. 7. Weinheim: Wiley-VCH VerlagGmbH&Co. KGaA.
230. Sandoval, M. A., Sloat, B. R., Lansakara, P. D., Kumar, A., Rodriguez, B. L., Kiguchi, K., et al. (2012). EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced antitumor activity. Journal of Controlled Release, 157, 287-296.
231. Sapra, P., & Allen, T. M. (2003). Ligand-targeted liposomal anticancer drugs. Progress in Lipid Research, 42, 439-462.
232. Saul, J. M., Annapragada, A. V., & Bellamkonda, R. V. (2006). A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. Journal of Controlled Release, 114, 277-287.
233. Savić, R., Eisenberg, A., & Maysinger, D. (2006). Block copolymer micelles as delivery vehicles of hydrophobic drugs: Micelle-cell interactions. Journal of Drug Targeting, 14, 343-355.
234. Schneider, G. F., Subr, V., Ulbrich, K., & Decher, G. (2009). Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy. Nano Letters, 9, 636-642.
235. Seki, T., Fang, J., & Maeda, H. (2009). Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Science, 100, 2426-2430.
236. Service, R. F. (2010). Nanotechnology. Nanoparticle Trojan horses gallop from the lab into the clinic. Science, 330, 314-315.
237. Sharma, S. K., Bagshawe, K. D., Reddy, L. H., & Couvreur, P. (2010). Antibody-directed enzyme prodrug therapy (ADEPT) for cancer macromolecular anticancer therapeutics (pp. 393-406). New York: Springer.
238. Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics, 154, 123-140.
239. 2-amino ester) nanoparticles as a pH-Sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Molecular Pharmaceutics, 2, 357-366.
240. Shepard, D. M., Ferris, M. C., Olivera, G. H., & Mackie, T. R. (1999). Optimizing the delivery of radiation therapy to cancer patients. SIAM Review, 41, 721-744.
241. Shi Kam, N. W., Jessop, T. C., Wender, P. A., & Dai, H. (2004). Nanotube molecular transporters: Internalization of carbon nanotube-protein conjugates into Mammalian cells. Journal of the American Chemical Society, 126, 6850-6851.
242. Shmeeda, H., Mak, L., Tzemach, D., Astrahan, P., Tarshish, M., & Gabizon, A. (2006). Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Molecular Cancer Therapeutics, 5, 818-824.
243. Shuai, X., Merdan, T., Schaper, A. K., Xi, F., & Kissel, T. (2004). Core-cross-linked polymeric micelles as paclitaxel carriers. Bioconjugate Chemistry, 15, 441-448.
244. Shubik, P. (1982). Vascularization of tumors: A review. Journal of Cancer Research and Clinical Oncology, 103, 211-226.
245. Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843-845.
246. Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29.
247. Simoes, S., Moreira, J. N., Fonseca, C., Duzgunes, N., & de Lima, M. C. (2004). On the formulation of pH-sensitive liposomes with long circulation times. Advanced Drug Delivery Reviews, 56, 947-965.
248. Singh, M. (1999). Transferrin as a targeting ligand for liposomes and anticancer drugs. Current Pharmaceutical Design, 5, 443-451.
249. Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. (2006). Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Molecular Cancer Therapeutics, 5, 1909-1917.
250. Sirsi, S., & Borden, M. (2009). Microbubble compositions, properties and biomedical applications. Bubble Science Engineering and Technology, 1, 3-17.
251. Smith, J. E., Medley, C. D., Tang, Z., Shangguan, D., Lofton, C., & Tan, W. (2007). Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Analytical Chemistry, 79, 3075-3082.
252. Soga, O., van Nostrum, C. F., Fens, M., Rijcken, C. J., Schiffelers, R. M., Storm, G., et al. (2005). Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. Journal of Controlled Release, 103, 341-353.
253. Sonavane, G., Tomoda, K., & Makino, K. (2008). Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids and Surfaces. B, Biointerfaces, 66, 274-280.
254. Sosabowski, J. K., Matzow, T., Foster, J. M., Finucane, C., Ellison, D., Watson, S. A., et al. (2009). Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. Journal of Nuclear Medicine, 50, 2082-2089.
255. Springer, C. J., Poon, G. K., Sharma, S. K., & Bagshawe, K. D. (1993). Identification of prodrug, active drug, and metabolites in an ADEPT clinical study. Cell Biophysics, 22, 9-26.
256. Stella, B., Arpicco, S., Peracchia, M. T., Desmaele, D., Hoebeke, J., Renoir, M., et al. (2000). Design of folic acid-conjugated nanoparticles for drug targeting. Journal of Pharmaceutical Sciences, 89, 1452-1464.
257. Storm, G., Belliot, S. O., Daemen, T., & Lasic, D. D. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews, 17, 31-48.
258. Straubinger, R. M., Hong, K., Friend, D. S., & Papahadjopoulos, D. (1983). Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles. Cell, 32, 1069-1079.
259. Stubbs, M., McSheehy, P. M., & Griffiths, J. R. (1999). Causes and consequences of acidic pH in tumors: A magnetic resonance study. Advances in Enzyme Regulation, 39, 13-30.
260. Sudimack, J., & Lee, R. J. (2000). Targeted drug delivery via the folate receptor. Advanced Drug Delivery Reviews, 41, 147-162.
261. Sun, L. C., & Coy, D. H. (2011). Somatostatin receptor-targeted anti-cancer therapy. Current Drug Delivery, 8, 2-10.
262. Sun, B., Ranganathan, B., & Feng, S. S. (2008). Multifunctional poly(D, L-lactideco-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials, 29, 475-486.
263. Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007). Functionalized micellar systems for cancer targeted drug delivery. Pharmaceutical Research, 24, 1029-1046.
264. Svenson, S., & Tomalia, D. A. (2005). Dendrimers in biomedical applications-reflections on the field. Advanced Drug Delivery Reviews, 57, 2106-2129.
265. Svenson, S., Wolfgang, M., Hwang, J., Ryan, J., & Eliasof, S. (2011). Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. Journal of Controlled Release, 153, 49-55.
266. Tagami, T., Ernsting, M. J., & Li, S.-D. (2011). Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. Journal of Controlled Release, 152, 303-309.
267. Taheri, A., Dinarvand, R., Atyabi, F., Ahadi, F., Nouri, F. S., Ghahremani, M. H., et al. (2011). Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with luteinizing hormone-releasing hormone (LHRH) peptide. International Journal of Molecular Sciences, 12, 4591-4608.
268. Tai, W., Mahato, R., & Cheng, K. (2010). The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release, 146, 264-275.
269. Tannock, I. F., & Rotin, D. (1989). Acid pH in tumors and its potential for therapeutic exploitation. Cancer Research, 49, 4373-4384.
270. Taratula, O., Garbuzenko, O. B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V. P., et al. (2009). Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. Journal of Controlled Release, 140, 284-293.
271. Tasis, D., Tagmatarchis, N., Bianco, A., & Prato, M. (2006). Chemistry of carbon nanotubes. Chemical Reviews, 106, 1105-1136.
272. Tejada-Berges, T., Granai, C. O., Gordinier, M., & Gajewski, W. (2002). Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Review of Anticancer Therapy, 2, 143-150.
273. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews. Drug Discovery, 4, 145-160.
274. Torrisi, M. R., Lotti, L. V., Belleudi, F., Gradini, R., Salcini, A. E., Confalonieri, S., et al. (1999). Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization. Molecular Biology of the Cell, 10, 417-434.
275. Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510.
276. Ulbrich, K., Etrych, T., Chytil, P., Jelinkova, M., & Rihova, B. (2003). HPMA copolymers with pH-controlled release of doxorubicin: In vitro cytotoxicity and in vivo antitumor activity. Journal of Controlled Release, 87, 33-47.
277. Ulrich, H., Martins, A. H., & Pesquero, J. B. (2005). RNA and DNA aptamers in cytomics analysis. Current Protocols in Cytometry, Chapter 7, Unit 7 28, 7.28.1-7.28.39.
278. Vasir, J. K., &Labhasetwar, V. (2005). Targeted drug delivery in cancer therapy. Technology in Cancer Research & Treatment, 4, 363-374.
279. Vega-Villa, K. R., Takemoto, J. K., Yanez, J. A., Remsberg, C. M., Forrest, M. L., & Davies, N. M. (2008). Clinical toxicities of nanocarrier systems. Advanced Drug Delivery Reviews, 60, 929-938.
280. Veikkola, T., Karkkainen, M., Claesson-Welsh, L.,&Alitalo, K. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Research, 60, 203-212.
281. Veiseh, O., Gunn, J. W., & Zhang, M. (2010). Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Advanced Drug Delivery Reviews, 62, 284-304.
282. Verbeek, B. S., Adriaansen-Slot, S. S., Vroom, T. M., Beckers, T., & Rijksen, G. (1998). Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Letters, 425, 145-150.
283. Vukelja, S. J., Anthony, S. P., Arseneau, J. C., Berman, B. S., Cunningham, C. C., Nemunaitis, J. J., et al. (2007). Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anti-Cancer Drugs, 18, 283-289.
284. Wang, J., Chen, P., Su, Z.-F., Vallis, K., Sandhu, J., Cameron, R., et al. (2001). Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nuclear Medicine and Biology, 28, 895-902.
285. Wang, S., Kim, G., Koo Lee, Y. E., Hah, H. J., Ethirajan, M., Pandey, R. K., et al. (2012). Multifunctional biodegradable polyacrylamide nanocarriers for cancer theranostics-A "see and treat" strategy. ACS Nano, 6, 6843-6851.
286. Watanabe, K., Kaneko, M., & Maitani, Y. (2012). Functional coating of liposomes using a folate-polymer conjugate to target folate receptors. International Journal of Nanomedicine, 7, 3679-3688.
287. Wicki, A., Rochlitz, C., Orleth, A., Ritschard, R., Albrecht, I., Herrmann, R., et al. (2012). Targeting tumor-associated endothelial cells: Anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clinical Cancer Research, 18, 454-464.
288. Wijagkanalan, W., Kawakami, S., & Hashida, M. (2011). Designing dendrimers for drug delivery and imaging: Pharmacokinetic considerations. Pharmaceutical Research, 28, 1500-1519.
289. Wileman, T., Harding, C., & Stahl, P. (1985). Receptor-mediated endocytosis. Biochemical Journal, 232, 1-14.
290. Wilson, C., & Szostak, J. W. (1998). Isolation of a fluorophore-specific DNA aptamer with weak redox activity. Chemical Biology, 5, 609-617.
291. Xu, L., Pirollo, K. F., & Chang, E. H. (1997). Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Human Gene Therapy, 8, 467-475.
292. Xu, L., Tang, W. H., Huang, C. C., Alexander, W., Xiang, L. M., Pirollo, K. F., et al. (2001). Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Molecular Medicine, 7, 723-734.
293. Yang, J., Chen, H., Vlahov, I. R., Cheng, J. X., & Low, P. S. (2007). Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. Journal of Pharmacology and Experimental Therapeutics, 321, 462-468.
294. Ying, X., Wen, H., Lu, W.-L., Du, J., Guo, J., Tian, W., et al. (2010). Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. Journal of Controlled Release, 141, 183-192.
295. Yokoyama, M. (2011). Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. Journal of Experimental & Clinical Medicine, 3, 151-158.
296. Yonezawa, S., Asai, T., & Oku, N. (2007). Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model. Journal of Controlled Release, 118, 303-309.
297. Yotsumoto, F., Sanui, A., Fukami, T., Shirota, K., Horiuchi, S., Tsujioka, H., et al. (2009). Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Research, 29, 4879-4885.
298. Young, D., Findlay, H. P., Hahn, S. E., Cechetto, L. M., McConkey, F., inventors, Arius Research Inc., assignee. (2007) Cytotoxicity mediation of cells evidencing surface expression of CD44. United States patent WO 2007098575, July 9.
299. Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010). Receptor-targeted nanocarriers for therapeutic delivery to cancer. Molecular Membrane Biology, 27, 286-298.
300. Zentner, G. M., Rathi, R., Shih, C., McRea, J. C., Seo, M. H., Oh, H., et al. (2001). Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. Journal of Controlled Release, 72, 203-215.
301. Zwick, E., Bange, J., & Ullrich, A. (2001). Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocrine-Related Cancer, 8, 161-173.